$IMVT News

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

Immunovant, Inc. Q1 2027 Earnings Call Summary

Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript

Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate

JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50

Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy

Citigroup Maintains Buy on Immunovant, Raises Price Target to $61

Immunovant Stock Gains 12.4% in a Month: What's Driving It?

Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary

H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data

Guggenheim Maintains Buy on Immunovant, Raises Price Target to $62

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Truist Securities Maintains Hold on Immunovant, Raises Price Target to $30

Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

B of A Securities Maintains Buy on Immunovant, Raises Price Target to $43

HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $40

Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial

Immunovant Q4 Earnings Call Highlights